Literature DB >> 8636100

Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases.

J Tözsér1, P Bagossi, I T Weber, T D Copeland, S Oroszlan.   

Abstract

The retroviral proteinase (PR) seems to play crucial roles in the viral life cycle, therefore it is an attractive target for chemotherapy. Previously we studied the specificity of human immunodeficiency virus (HIV) type 1 and type 2 as well as equine infectious anemia virus PRs using oligopeptide substrates. Here a similar approach is used to characterize the specificity of avian myeloblastosis virus (AMV) PR and to compare it with those of the previously characterized lentiviral PRs. All peptides representing naturally occurring Gag and Gag-Pol cleavage sites were substrates of the AMV PR. Only half of these peptides were substrates of HIV-1 PR. The Km values for AMV PR were in a micromolar range previously found for the lentiviral PRs; however, the kcat values were in a 10 30-fold lower range. A series of peptides containing single amino acid substitutions in a sequence representing a naturally occurring HIV cleavage site was used to characterize the seven substrate binding subsites of the AMV PR. The largest differences were found at the P4 and P2 positions of the substrate. Detailed analysis of the results by molecular modeling and comparison with previously reported data revealed the common characteristics of the specificity of the retroviral PRs as well as its strong dependence on the sequence context of the substrate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636100     DOI: 10.1074/jbc.271.12.6781

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

Authors:  Péter Bagossi; Tamás Sperka; Anita Fehér; János Kádas; Gábor Zahuczky; Gabriella Miklóssy; Péter Boross; József Tözsér
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Molecular mechanics calculations on Rous sarcoma virus protease with peptide substrates.

Authors:  I T Weber; R W Harrison
Journal:  Protein Sci       Date:  1997-11       Impact factor: 6.725

3.  Specificity of Retroviral Proteinases Based on Substrates Containing Tyrosine and Proline at the Site of Cleavage.

Authors:  József Tözsér
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

4.  Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.

Authors:  Helga Eizert; Pálma Bander; Péter Bagossi; Tamás Sperka; Gabriella Miklóssy; Péter Boross; Irene T Weber; József Tözsér
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

5.  Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.

Authors:  Andrey Y Kovalevsky; Alexander A Chumanevich; Fengling Liu; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2007-12-04       Impact factor: 3.162

6.  Comparative studies on retroviral proteases: substrate specificity.

Authors:  József Tözsér
Journal:  Viruses       Date:  2010-01-14       Impact factor: 5.818

7.  Mutations affecting cleavage at the p10-capsid protease cleavage site block Rous sarcoma virus replication.

Authors:  Marcy L Vana; Aiping Chen; Peter Boross; Irene Weber; Dalbinder Colman; Eric Barklis; Jonathan Leis
Journal:  Retrovirology       Date:  2005-09-27       Impact factor: 4.602

8.  A look inside HIV resistance through retroviral protease interaction maps.

Authors:  Aleksejs Kontijevskis; Peteris Prusis; Ramona Petrovska; Sviatlana Yahorava; Felikss Mutulis; Ilze Mutule; Jan Komorowski; Jarl E S Wikberg
Journal:  PLoS Comput Biol       Date:  2007-01-24       Impact factor: 4.475

9.  Biochemical characterization of Ty1 retrotransposon protease.

Authors:  Lívia Diána Gazda; Krisztina Joóné Matúz; Tibor Nagy; János András Mótyán; József Tőzsér
Journal:  PLoS One       Date:  2020-01-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.